Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Marker Therapeutics

14/08/2026 22:35

Marker Therapeutics Inc MRKR.OQ reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -29 cents.  The mean expectation of three analysts for the quarter was for a loss of 22 cents per share. Wall Street expected results to range from -29 cents to -16 cents per share.
Revenue fell 20.9% to $681.00 thousand from a year ago; analysts expected $682.00 thousand. 
Marker Therapeutics Inc's reported EPS for the quarter was a loss of 9 cents​.
The company reported a quarterly loss of $1.83 million.
Marker Therapeutics Inc shares had fallen by 24.5% this quarter and lost 25.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Marker Therapeutics Inc is $8.00, about 86.1% above its last closing price of $1.11
This summary was machine generated from LSEG data August 14 at 09:34 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.22
-0.09
Beat
Mar. 31 2026 
-0.18
-0.16
Beat
Dec. 31 2025 
-0.20
-0.09
Beat
Sep. 30 2025 
-0.45
-0.12
Beat